Open AccessClinical Study of the Use of the New Aminoglycoside Tobramycin for Therapy of Infections Due to Gram-Negative Bacteria
Author(s) -
Gabriel Jaffé,
William D. Ravreby,
Burt R. Meyers,
Shalom Z. Hirschman
Publication year - 1974
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.5.1.75
Subject(s) - tobramycin , aminoglycoside , enterobacter cloacae , microbiology and biotechnology , medicine , enterobacter , superinfection , serratia marcescens , staphylococcus aureus , klebsiella pneumoniae , antimicrobial , antibiotics , proteus mirabilis , gentamicin , escherichia coli , biology , immunology , bacteria , biochemistry , virus , genetics , gene
Tobramycin, a new aminoglycoside antimicrobial, was evaluated as therapy for infections due to gram-negative bacilli in 15 seriously ill patients with underlying diseases. Three of 10 patients with gram-negative bacteremias also had urinary tract infections. Two patients had respiratory tract infections, one had cellulitis, one had a urinary tract infection, and another had septic phlebitis. Twelve patients were cured of their infections. Eosinophilia was observed in one patient and another developed superinfection withStaphylococcus aureus after 6 days of tobramycin therapy. There were five isolates ofEscherichia coli , five ofKlebsiella sp., two ofPseudomonas sp., and one each ofEnterobacter agglomerans, Serratia marcescens , andEnterobacter cloacae . The average serum concentration of tobramycin 2 h after a parenteral dose of 1.0 to 1.5 mg/kg was 5.1 μg/ml; higher concentrations of tobramycin were present in urine. Tobramycin proved to be an effective antimicrobial in these patients.